Abstract

Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Plasma biomarkers of amyloid beta (Aβ)40, Aβ42 , total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n=445) and non-Hispanic Whites (n=520). Dyslipidemia was associated with elevated Aβ40 (P=.01) and Aβ42 (P=.001) while hypertension was associated with elevated Aβ40 (P=.003), Aβ42 (P<.001), and total tau (P=.002) levels. Diabetes was associated with higher Aβ40 (P<.001), Aβ42 (P<.001), total tau (P<.001), and NfL (P<.001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ40 (P<.001), Aβ42 (P<.001), total tau (P<.001), and NfL (P<.001) levels. Mexican Americans had significantly lower Aβ40 (P<.001) and higher total tau (P=.005) levels. Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.